FDA Staff Doubt Melanoma Drug RP1 Shows Benefit

FDA staff have voiced significant doubts regarding the clinical benefit of RP1 (vusolimogene oderparepvec), a drug candidate intended for the treatment of melanoma. This skepticism comes ahead of a crucial meeting of the FDA's external advisory committee, which will deliberate on the drug's potential for accelerated approval. RP1 has faced rejection from the U.S. Food and Drug Administration on two prior occasions, highlighting persistent concerns about its efficacy and the robustness of the supporting data.

According to briefing documents released by the FDA, agency staff found the evidence presented by the developer, Replimune, to be unconvincing. The primary concern centers on whether RP1 demonstrates a clear and statistically significant clinical benefit that outweighs its potential risks. The drug is an oncolytic immunotherapy designed to selectively infect and kill cancer cells while stimulating an anti-tumor immune response. Its mechanism involves delivering a gene that encodes for granulocyte-macrophage colony-stimulating factor (GM-CSF) into tumor cells, aiming to enhance the body's immune system to fight the cancer.

The current submission for RP1 is based on data from a Phase 2 trial, which included patients with unresectable melanoma who had progressed on or after treatment with a PD-1-based therapy. The trial aimed to evaluate the drug's efficacy in terms of objective response rate (ORR) and duration of response (DoR). However, FDA staff noted that the observed response rates, while showing some activity, did not meet the predefined endpoints with sufficient statistical power to definitively establish clinical benefit. Concerns were also raised about the durability of responses and the overall survival data, which have been inconsistent or insufficient in previous submissions.

Replimune's strategy for RP1 has been to pursue accelerated approval, a pathway designed to expedite the availability of promising new drugs for serious or life-threatening conditions based on surrogate endpoints that are reasonably likely to predict clinical benefit. However, the FDA's review process suggests that the data provided for RP1 may not meet the threshold for this expedited pathway. The agency staff's assessment indicates a need for more definitive evidence of clinical benefit, potentially requiring further trials or additional data analysis to satisfy regulatory requirements. The upcoming advisory committee meeting will provide an opportunity for external experts to review the data and offer their recommendations to the FDA, which, while not binding, carries significant weight in the final approval decision.